Literature DB >> 15182217

Time course of response to antidepressants in late-life major depression: therapeutic implications.

Ellen M Whyte1, Mary Amanda Dew, Ariel Gildengers, Eric J Lenze, Ashok Bharucha, Benoit H Mulsant, Charles F Reynolds.   

Abstract

In the treatment of depression, there is considerable interest in the time course of response and, in particular, the speed with which individuals recover from depressive episodes. Examination of the time course and speed of response is critical for assessing the usefulness of specific treatments. However, while this issue has received attention in mid-life adult populations, it has received little consideration in the context of late-life major depression. The synthesis of empirical reports indicates that, while older adults with depression seem to respond with the same speed as mid-life adults, several factors have consistently been associated with reduced speed of response to antidepressant treatment, including greater severity of depressive symptoms and co-occurring anxiety symptoms. Limited evidence suggests that sleep impairment and genetic factors (e.g. presence of the s allele of the serotonin transporter gene promoter region) may also be associated with reduced speed of response. Some factors have consistently been found to be unrelated to speed of response (demographic characteristics, nonpsychiatric physical illnesses) whereas other factors have only mixed evidence supporting any effect (psychosocial and other clinical factors). While there is little work available to date, some evidence suggests that time course and speed of response affect longer-term outcomes of depression pharmacotherapy; thus, older adults with more rapid versus slower patterns of response may differ in the types of maintenance treatment needed to avert additional depressive episodes. None of potential strategies for accelerating speed of response have been clearly shown to be effective in late-life depression. Future treatment studies for late-life depression should routinely consider not only overall efficacy of a given pharmacotherapy (i.e. total rate of response), but time course and speed of response. To this end, new investigations must be designed to overcome the methodological limitations of prior studies that have examined time course and they should include a range of potential covariates and outcomes of between-patient differences in speed of response. Better understanding of factors related to such differences may suggest new intervention strategies to accelerate response. Copyright 2004 Adis Data Information BV

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182217     DOI: 10.2165/00002512-200421080-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  78 in total

1.  Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.

Authors:  B G Pollock; R E Ferrell; B H Mulsant; S Mazumdar; M Miller; R A Sweet; S Davis; M A Kirshner; P R Houck; J A Stack; C F Reynolds; D J Kupfer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  Comorbid anxiety disorders in late-life depression.

Authors:  B H Mulsant; C F Reynolds; M K Shear; R A Sweet; M Miller
Journal:  Anxiety       Date:  1996

3.  A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.

Authors:  P A Newhouse; K R Krishnan; P M Doraiswamy; E M Richter; E D Batzar; C M Clary
Journal:  J Clin Psychiatry       Date:  2000-08       Impact factor: 4.384

4.  How long does it take for antidepressant therapies to act?

Authors:  G Parker; K Roy; D B Menkes; J Snowdon; P Boyce; D Grounds; B Hughson; C Stringer
Journal:  Aust N Z J Psychiatry       Date:  2000-02       Impact factor: 5.744

5.  Occurrence and course of suicidality during short-term treatment of late-life depression.

Authors:  Katalin Szanto; Benoit H Mulsant; Patricia Houck; Mary Amanda Dew; Charles F Reynolds
Journal:  Arch Gen Psychiatry       Date:  2003-06

6.  An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.

Authors:  Lon S Schneider; J Craig Nelson; Cathryn M Clary; Paul Newhouse; K Ranga Rama Krishnan; Thomas Shiovitz; Karen Weihs
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

7.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

8.  Recovery in geriatric depression.

Authors:  G S Alexopoulos; B S Meyers; R C Young; T Kakuma; M Feder; A Einhorn; E Rosendahl
Journal:  Arch Gen Psychiatry       Date:  1996-04

9.  Treatment of 70(+)-year-olds with recurrent major depression. Excellent short-term but brittle long-term response.

Authors:  C F Reynolds; E Frank; M A Dew; P R Houck; M Miller; S Mazumdar; J M Perel; D J Kupfer
Journal:  Am J Geriatr Psychiatry       Date:  1999       Impact factor: 4.105

10.  How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo.

Authors:  G D Tollefson; S L Holman
Journal:  Int Clin Psychopharmacol       Date:  1994       Impact factor: 1.659

View more
  27 in total

Review 1.  Depression care for the elderly: reducing barriers to evidence-based practice.

Authors:  Kathleen Ell
Journal:  Home Health Care Serv Q       Date:  2006

2.  Remission in depressed geriatric primary care patients: a report from the PROSPECT study.

Authors:  George S Alexopoulos; Ira R Katz; Martha L Bruce; Moonseong Heo; Thomas Ten Have; Patrick Raue; Hillary R Bogner; Herbert C Schulberg; Benoit H Mulsant; Charles F Reynolds
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

3.  Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.

Authors:  Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant
Journal:  Depress Anxiety       Date:  2019-11-04       Impact factor: 6.505

4.  Socioeconomic status and anxiety as predictors of antidepressant treatment response and suicidal ideation in older adults.

Authors:  Alex Cohen; Stephen E Gilman; Patricia R Houck; Katalin Szanto; Charles F Reynolds
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-09-25       Impact factor: 4.328

5.  Does age at onset have clinical significance in older adults with bipolar disorder?

Authors:  David Chu; Ariel G Gildengers; Patricia R Houck; Stewart J Anderson; Benoit H Mulsant; Charles F Reynolds; David J Kupfer
Journal:  Int J Geriatr Psychiatry       Date:  2010-12       Impact factor: 3.485

6.  Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults.

Authors:  Stephen F Smagula; Meryl A Butters; Stewart J Anderson; Eric J Lenze; Mary Amanda Dew; Benoit H Mulsant; Francis E Lotrich; Howard Aizenstein; Charles F Reynolds
Journal:  JAMA Psychiatry       Date:  2015-10       Impact factor: 21.596

7.  Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.

Authors:  Ramin Saghafi; Charlotte Brown; Meryl A Butters; Jill Cyranowski; Mary Amanda Dew; Ellen Frank; Ariel Gildengers; Jordan F Karp; Eric J Lenze; Francis Lotrich; Lynn Martire; Sati Mazumdar; Mark D Miller; Benoit H Mulsant; Elizabeth Weber; Ellen Whyte; Jennifer Morse; Jacqueline Stack; Patricia R Houck; Salem Bensasi; Charles F Reynolds
Journal:  Int J Geriatr Psychiatry       Date:  2007-11       Impact factor: 3.485

Review 8.  Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age.

Authors:  Henry C Driscoll; Jordan F Karp; Mary Amanda Dew; Charles F Reynolds
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.

Authors:  Francis E Lotrich; Bruce G Pollock; Margaret Kirshner; Robert F Ferrell; Charles F Reynolds Iii
Journal:  J Psychiatry Neurosci       Date:  2008-03       Impact factor: 6.186

10.  FKBP5 polymorphisms and antidepressant response in geriatric depression.

Authors:  Jane E Sarginson; Laura C Lazzeroni; Heather S Ryan; Alan F Schatzberg; Greer M Murphy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.